Home     |     About us     |     Facility     |     Products     |     Accolades     |     Business Alliance     |     Company News     |     Career with us     |     Contact Info   
 
 

Contact Address

Neopharma
Plot A-1 89-95, Industrial City of Abu Dhabi (ICAD),
Mussafah, P O Box 72900, Abu Dhabi,
United Arab Emirates

Tel: +971 2 550 1000
Fax: +971 2 550 1199
Email: neopharma@neopharma.ae


View Neopharma in a larger map

 

 


2012
  • Ministry of Health approves Neopharma to launch its generic version of Levofloxacin and Losartan Potassium.
  • Neopharma launches ‘’Renalka’’ Urinary alkalinizer – A quick remedy for pH balance
  • Neopharma organizes voluntary blood donation campaign in collaboration with the Abu Dhabi Blood Bank on 16th September 2012 in the Company premises.
  • Neopharma receives approval for the launch of generic version of Pantoprazole 40mg gastro resistant tablets.
  • Neopharma launches generic version of Gliclazide Modified Release Tablets.
  • Neopharma, Abu Dhabi’s leading generic pharmaceutical manufacturing facility inaugurated its dedicated world class research and development centre in Musaffah on September 10th, 2012. The research centre has collaborated with the Arkansas University for the development of microfiber nanotechnology for glucose sensors and nanotechnology based microchips for neurodegenerative disorders.


2011
  • Neopharma makes its foray into CIS Markets with product launches in Tajikistan.
  • Neopharma introduces generic version of anti-diarrheal drug Loperamide in UAE.
  • Neopharma begins marketing of its first injectable product “Advacef”.
  • Neopharma launches generic version of Ivy Leaf extract Syrup.
  • Neopharma receives approval for the launch of generic version of Gliclazide Modified Release Tablets.
  • Neopharma receives approval for the launch of Urinary Alkalinizer, Fluconazole tablets and low osmolarity formula of Oral Rehydration Salts
  • Neopharma further expands operations in the African Market by starting the registration process in Ethiopia and Tanzania.
  • Registration of first set of products completed in Turkmenistan.
  • The UAE Genetic Diseases Association and Neopharma have joined hands for introducing Manal. The launch of Manal will form an integral part of the UAE GDA vision to prevent neural tube defects in the United Arab Emirates by Health Education, Public Awareness and Folic Acid Supplementation targeted for specific population.


2010
  • Neopharma has received the Certificate of EHS approval from the Abu Dhabi Emirate, Environment, Health and Safety Management System.


2009
  • Products are introduced into one of the biggest markets in the region – Saudi Arabia
  • Neopharma starts Kuwait operations
  • Neopharma moves into horizontal integration mode.  Ground breaking ceremony heralds the start of new manufacturing facilities.


2008
  • Neopharma starts operations in the Sultanate of Oman.
  • Neopharma becomes the first pharmaceutical company in the region to obtain the integrated management system encompassing ISO 9001, ISO 14001 & OHSAS 18001.
  • Contract manufacturing for Lagap, Switzerland
  • Neopharma enters the Qatar pharmaceutical market
  • The first exports to East Africa commences with dispatch to Kenya
  • Neopharma enters the Afghanistan markets


More Updates... | Mouse hover to pause scrolling


 
 

Copyright neopharma.ae 2010  |  All Rights Reserved    |    MOH Approval License no : 1931-2-7-29-7-14
Home   |   Feedback   |   Terms of use